CRXT · Clarus Therapeutics Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.05M | $4.01M | - | $2.22M | - | - | - | - |
| Cost of Revenue | $1.16M | $367.0K | - | $510.0K | - | - | - | - |
| Gross Profit | $2.23M | $3.35M | - | $3.78M | - | - | - | - |
| R&D | $606.0K | $881.0K | - | $1.27M | - | - | - | - |
| SG&A | - | - | - | - | $807.1K | - | - | - |
| Total Operating Expenses | $13.54M | $16.89M | - | $12.21M | - | - | - | - |
| D&A | - | $5.0K | - | - | - | - | - | - |
| Operating Income | ($18.11M) | ($15.43M) | - | $5.41M | - | - | - | - |
| Interest Expense | $2.02M | $1.97M | - | $4.45M | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - |
| Net Income | ($10.69M) | ($14.87M) | - | $5.41M | ($2.60M) | $10.65M | - | - |
| EPS - Basic | ($0.24) | - | - | $1.10 | - | - | - | - |
| EPS - Diluted | $0.00 | - | - | ($0.63) | - | - | - | - |
Balance Sheet
| Line item | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19.17M | $9.14M | $26.41M | $13.15M | $224.5K | $408.2K | $655.4K | - |
| Accounts Receivable | $8.71M | $8.01M | $6.34M | $6.93M | - | - | - | - |
| Inventory | $16.80M | $14.93M | $14.21M | $12.48M | - | - | $13.70M | - |
| Accounts Payable | $8.49M | $14.06M | $13.95M | $15.84M | $117.9K | $83.1K | $178.6K | - |
| Current Assets | $48.88M | $36.45M | $51.64M | $45.26M | $340.0K | $593.1K | $823.5K | - |
| Total Assets | $48.94M | $36.52M | $51.71M | $45.32M | $58.99M | $59.24M | $59.47M | - |
| Current Liabilities | $61.81M | $65.95M | $66.06M | $64.38M | $1.34M | $696.0K | $420.8K | - |
| Long-term Debt | - | - | - | - | - | - | - | - |
| Total Liabilities | $62.00M | $66.88M | $67.63M | $70.85M | $10.60M | $8.26M | $19.13M | - |
| Stockholders' Equity | ($13.06M) | ($30.36M) | ($15.92M) | ($25.52M) | $24.2K | $5.00M | $5.00M | ($316.27M) |
| Retained Earnings | ($347.22M) | ($336.52M) | ($321.65M) | ($317.35M) | $2.40M | $5.00M | ($4.72M) | - |
Cash Flow
| Line item | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($17.27M) | - | - | - | ($226.6K) | - | - |
| Investing Cash Flow | - | ($11.0K) | - | - | - | - | - | - |
| Financing Cash Flow | - | $0 | - | - | - | ($20.6K) | - | - |
| CapEx | - | $11.0K | - | - | - | - | - | - |
| Free Cash Flow | - | ($17.28M) | - | - | - | - | - | - |
Ratios
| Metric | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||
| Gross margin | 54.9% | 83.4% | - | 169.8% | - | - | - | - |
| Operating margin | -447.3% | -384.7% | - | 243.1% | - | - | - | - |
| EBITDA margin | - | -384.5% | - | - | - | - | - | - |
| Net margin | -264.0% | -370.7% | - | 243.1% | - | - | - | - |
| Free cash flow margin | - | -430.8% | - | - | - | - | - | - |
| FCF / Net income | - | 1.16 | - | - | - | - | - | - |
| R&D / Revenue | 15.0% | 22.0% | - | 57.3% | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - |
| Return on assets | -21.9% | -40.7% | - | 11.9% | -4.4% | 18.0% | - | - |
| Return on equity | 81.9% | 49.0% | - | -21.2% | -10715.4% | 212.9% | - | - |
| Return on invested capital | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||
| Current ratio | 0.79 | 0.55 | 0.78 | 0.70 | 0.25 | 0.85 | 1.96 | - |
| Quick ratio | 0.52 | 0.33 | 0.57 | 0.51 | 0.25 | 0.85 | -30.60 | - |
| Cash ratio | 0.31 | 0.14 | 0.40 | 0.20 | 0.17 | 0.59 | 1.56 | - |
| Leverage | ||||||||
| Debt / Equity | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest coverage | -9.0x | -7.9x | - | 1.2x | - | - | - | - |
| Equity multiplier | -3.75 | -1.20 | -3.25 | -1.78 | 2433.80 | 11.85 | 11.89 | - |
| Liabilities / Assets | 1.27 | 1.83 | 1.31 | 1.56 | 0.18 | 0.14 | 0.32 | - |
| Efficiency | ||||||||
| Asset turnover | 0.08 | 0.11 | - | 0.05 | - | - | - | - |
| Inventory turnover | 0.07 | 0.02 | - | 0.04 | - | - | - | - |
| Days sales outstanding | 785d | 728d | - | 1138d | - | - | - | - |
| Days inventory outstanding | 5288d | 14849d | - | 8932d | - | - | - | - |
| Days payable outstanding | 2671d | 13979d | - | 11339d | - | - | - | - |
| Cash conversion cycle | 3402d | 1598d | - | -1269d | - | - | - | - |
| Valuation | ||||||||
| P / E | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| Growth | ||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - | - | - | - |
| Net income growth (YoY) | -311.7% | - | - | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | - | - | - | - | - | - | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Clarus Therapeutics Holdings against the 5 most active filers in the same SIC group.